Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching
- PMID: 16338451
- DOI: 10.1016/S0140-6736(05)67813-0
Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching
Abstract
Background: Human embryonic stem (hES) cells are a promising source for transplantation to replace diseased or damaged tissue, but their differentiated progeny express human leucocyte antigens (HLAs) that will probably cause graft rejection. The creation of a bank of HLA-typed hES cells, from which a best match could be selected, would help reduce the likelihood of graft rejection. We investigated how many hES cell lines would be needed to make matching possible in most cases.
Methods: The number of hES cell lines needed to achieve varying degrees of HLA match was estimated by use of, as a surrogate for hES-cell donor embryos, blood group and HLA types on a series of 10,000 consecutive UK cadaveric organ donors. The degree of blood group compatibility and HLA matching for a recipient population consisting of 6577 patients registered on the UK kidney transplant waiting list was determined, assuming all donor hES cell lines could provide a transplant for an unlimited number of recipients.
Findings: A bank of 150 consecutive donors provided a full match at HLA-A, HLA-B, and HLA-DR for a minority of recipients (<20%); a beneficial match (defined as one HLA-A or one HLA-B mismatch only) or better for 37.9% (range 27.9-47.5); and an HLA-DR match or better for 84.9% (77.5-90.0). Extending the number of donors beyond 150 conferred only a very gradual incremental benefit with respect to HLA matching. A panel of only ten donors homozygous for common HLA types selected from 10,000 donors provided a complete HLA-A, HLA-B and HLA-DR match for 37.7% of recipients, and a beneficial match for 67.4%.
Interpretation: Approximately 150 consecutive blood group compatible donors, 100 consecutive blood group O donors, or ten highly selected homozygous donors could provide the maximum practical benefit for HLA matching. The findings from these simulations have practical, political, and ethical implications for the establishment of hES-cell banks.
Comment in
-
Stem-cell banking: the size of the task.Lancet. 2005 Dec 10;366(9502):1991-2. doi: 10.1016/S0140-6736(05)67797-5. Lancet. 2005. PMID: 16338440 No abstract available.
-
Estimating human embryonic stem-cell numbers.Lancet. 2006 Feb 25;367(9511):650. doi: 10.1016/S0140-6736(06)68261-5. Lancet. 2006. PMID: 16503462 No abstract available.
Similar articles
-
Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy.Stem Cells. 2007 Apr;25(4):983-5. doi: 10.1634/stemcells.2006-0566. Epub 2006 Dec 21. Stem Cells. 2007. PMID: 17185611
-
Evaluation of 28 human embryonic stem cell lines for use as unrelated donors in stem cell therapy: implications of HLA and ABO genotypes.Cell Transplant. 2010;19(11):1383-95. doi: 10.3727/096368910X513991. Epub 2010 Jun 29. Cell Transplant. 2010. PMID: 20587141
-
Immunological considerations for embryonic and induced pluripotent stem cell banking.Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12;366(1575):2312-22. doi: 10.1098/rstb.2011.0030. Philos Trans R Soc Lond B Biol Sci. 2011. PMID: 21727137 Free PMC article. Review.
-
Effect of human leukocyte antigen-C and -DQ matching on pediatric heart transplant graft survival.J Heart Lung Transplant. 2014 Dec;33(12):1282-7. doi: 10.1016/j.healun.2014.07.014. Epub 2014 Jul 22. J Heart Lung Transplant. 2014. PMID: 25128416 Free PMC article.
-
HLA compatibility and organ transplant survival. Collaborative Transplant Study.Rev Immunogenet. 1999;1(3):334-42. Rev Immunogenet. 1999. PMID: 11256424 Review.
Cited by
-
Submission to Stem Cells Reviews and Reports.Stem Cell Rev Rep. 2024 Sep 14. doi: 10.1007/s12015-024-10783-7. Online ahead of print. Stem Cell Rev Rep. 2024. PMID: 39276260 Review.
-
The impact of consanguinity on the design of iPSC banks.Stem Cell Reports. 2024 Aug 13;19(8):1043-1047. doi: 10.1016/j.stemcr.2024.06.004. Epub 2024 Jul 11. Stem Cell Reports. 2024. PMID: 38996491 Free PMC article.
-
Stem cell therapies: a new era in the treatment of multiple sclerosis.Front Neurol. 2024 May 9;15:1389697. doi: 10.3389/fneur.2024.1389697. eCollection 2024. Front Neurol. 2024. PMID: 38784908 Free PMC article. Review.
-
Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules. 2024 Apr 21;14(4):503. doi: 10.3390/biom14040503. Biomolecules. 2024. PMID: 38672519 Free PMC article. Review.
-
Clinical translation of pluripotent stem cell-based therapies: successes and challenges.Development. 2024 Apr 1;151(7):dev202067. doi: 10.1242/dev.202067. Epub 2024 Apr 2. Development. 2024. PMID: 38564308 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials